ALK陽性肺癌病患：使用Lorlatinib達到最長無惡化存活時間 ALK-Positive Lung Cancer Patients: Achieving the Longest PFS

這段影片將探討ALK陽性肺癌病患使用Lorlatinib達到的最長無惡化存活時間。Lorlatinib作為一種先進的標靶治療藥物，顯示出顯著的療效和延長病患無惡化存活期的能力。我們將分享最新的研究數據和臨床試驗結果，讓觀眾了解這種治療方法的潛在益處和未來發展方向。

This video explores the longest progression-free survival time achieved by ALK-positive lung cancer patients using Lorlatinib. As an advanced targeted therapy, Lorlatinib has shown remarkable efficacy in extending progression-free survival. We will share the latest research data and clinical trial results, providing insights into the potential benefits and future developments of this treatment approach.